Drug intelligence / Profile preview

Orna circular RNA infectious disease vaccine

Development stage: Preclinical
Lead developer: Orna Therapeutics
Modality: RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Orna Therapeutics-protective antigens-circular RNA vaccine (oRNA)-LNP delivery-infectious diseases refers to a preclinical research program focused on developing circular RNA (oRNA) vaccines for infectious diseases. Developed by Orna Therapeutics in collaboration with Merck (MSD), the platform utilizes proprietary oRNA technology where linear RNA is circularized to create highly stable molecules with reduced immunogenicity and extended protein expression compared to traditional linear mRNA. These oRNA molecules are engineered to encode protective antigens against various infectious disease pathogens and are encapsulated in lipid nanoparticles (LNPs) for efficient delivery. The collaboration with Merck, initiated in 2022, aims to develop multiple circular RNA-based vaccines and therapeutics, leveraging the potential of oRNA to provide superior durability and efficacy in preventing infectious diseases.

Other names: Orna Therapeutics-protective antigens-circular RNA vaccine (oRNA)-LNP delivery-infectious diseasesoRNA infectious disease vaccine

Targets

PA (Influenza polymerase acidic protein)

Beyond the preview

Go deeper on Orna circular RNA infectious disease vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orna circular RNA infectious disease vaccine.

Explore the full profile